https://allsci.com/news/biotech/pm647-fda-clearance-prime-medicine-receives-for/ AllScien 2026-09-28T13:59:31.365055Z Prime Medicine receives FDA clearance for PM647 in alpha-1 antitrypsin deficiency https://allsci.com/news/biotech/ctdna-recovery-am-01-amplifyer-bios-shows-up-to/ AllScien 2026-09-28T13:44:49.062209Z Amplifyer Bio humanized priming agent boosts ctDNA recovery up to 100-fold in mice https://allsci.com/news/approvals/gazyva-fda-approval-nephrotic-syndrome-approves/ AllScien 2026-09-28T13:16:44.228357Z FDA approves Gazyva to reduce relapse risk in pediatric idiopathic nephrotic syndrome https://allsci.com/news/biotech/car-t-therapy-myeloma-iasos-in-vivo-achieves-90/ AllScien 2026-09-28T13:05:14.831936Z IASO Bio’s in vivo BCMA CAR-T posts 90% response rate in first human study https://allsci.com/news/biotech/ifinatamab-deruxtecan-fda-rejection-rejects-bla/ AllScien 2026-09-28T12:04:25.817822Z Daiichi Sankyo, Merck withdraw ifinatamab deruxtecan BLA in ES-SCLC https://allsci.com/news/approvals/atebrioz-fda-approval-approves-first-oral-alk2/ AllScien 2026-09-28T11:23:49.227722Z Incyte takes FDA approval for Atebrioz as first oral ALK2i for fibrodysplasia ossificans progressiva https://allsci.com/news/regulatory-setbacks-safety/aumolertinib-marketing-authorization-revoked/ AllScien 2026-09-28T09:58:10.674240Z EC revokes Hansoh’s aumolertinib approval over data protection breach https://allsci.com/news/business/celularity-funding-recapitalization-closes-usd/ AllScien 2026-09-28T09:25:47.187780Z Celularity raises USD 10m in first tranche of USD 28m recapitalization https://allsci.com/news/business/ligand-avencell-car-t-funding-commits-usd-41m/ AllScien 2026-09-28T09:02:00.588743Z Ligand backs AvenCell CAR-T pipeline with up to USD 47m https://allsci.com/news/business/scancell-blackrock-melanoma-trial-funding/ AllScien 2026-09-28T08:31:09.361907Z Scancell secures USD 25m debt facility from BlackRock to fund iSCIB1+ Phase III melanoma trial